Stryker Shares Plunge Over Persistent Manufacturing Issues
News related to:Stryker Corporation · 1 min read
SAN FRANCISCO, Sept. 16, 2026 /CourierPR/ -- Stryker Corporation, a leading medical technology company, faced a significant setback in its stock price and market valuation after disclosing ongoing issues with its Peripheral Vascular operations. On September 8, 2026, Stryker's shares plummeted by 8.8%, losing over $10 billion in market capitalization. The decline followed a revelation by the company’s Chief Financial Officer (CFO), Preston Wells, during a Wells Fargo Healthcare Conference, that a manufacturing problem in the Peripheral Vascular unit was persisting into the third quarter and would continue into the fourth quarter as well.
The issue initially came to light in July 2026, when Stryker reported its Q2 2026 results.
Despite these assurances, the problem persisted, leading to further negative market reactions.
The ongoing nature of the issue has drawn scrutiny from national shareholders' rights firm Hagens Berman. The firm is now investigating whether Stryker was sufficiently transparent about the problem and whether the company may have violated federal securities laws. Hagens Berman encourages Stryker investors who suffered substantial losses to submit their losses and invites persons with knowledge of the situation to contact the firm’s attorneys.
Stryker acquired Inari in February 2025 to supplement its Peripheral Vascular reporting unit.
The developments have raised concerns among investors and stakeholders about the reliability of Stryker’s management and the transparency of its operations. As the investigation continues, the company faces potential legal and financial repercussions, which could impact its reputation and future business prospects.